 To evaluate the safety, tolerability, dose limiting toxicity DLT, and maximum tolerated dose MTD, of FS102BMS-986186 when administered intravenously IV to subjects with relapsed or refractory solid tumors that overexpress HER2 and who have no standard treatment options. 